Glaucoma Therapeutics Market projecting a CAGR of 2.96% during the forecast period, 2020-2026

Published | March 2020

According to BlueWeave Consulting, the global Glaucoma Therapeutics market has reached USD 6.27 Billion in 2019 and estimated to reach USD 7.65 Billion in 2026 and anticipated to grow by CAGR of 2.96% during the forecast period 2020-2026. Glaucoma prevalence is oriented towards the geriatric population, and the rising geriatric population globally is likely to have a positive impact on the global market.

Glaucoma has affected about 64 million people worldwide. Glaucoma is a condition that can affect the optic nerve, and any level of glaucoma can result in partial or complete blindness. The severity of glaucoma has led to increased awareness among end-users of ways to manage glaucoma, and people realized the importance of early detection and treatment of this disease. Besides, improved diagnostic tools for glaucoma diagnosis are likely to favor the development of the global Glaucoma Therapeutics Market in the years ahead. These are high glaucoma prevalence, enhanced technical support during diagnosis, and increased awareness of glaucoma-related care. Such factors will push the global market for glaucoma therapy to the forefront. With the introduction of pipeline products during the forecast period for the launch of late-stage products into the glaucoma market. The drugs include the DE-117 drug from Santen and another with unspecified MOA, Roclatan fixed-dose combination therapy from Aerie, and two Sustained-release (SR) implants.

Transforming lifestyle is one of the key factors for driving global Glaucoma Therapeutics market in upcoming years

Changing a lifestyle where people spend a lot of time in front of a smart gadget which emits blue ray. This introduction now begins at a very early age. It is also common in older generations who are more vulnerable to such diseases than younger-age individuals. The rise in the geriatric population can also be seen to determine the future direction for the glaucoma therapy market. There are also various treatments available to counter the problem. One such is the relatively inexpensive and precise laser treatment. In addition, increasing patient awareness of glaucoma and the introduction of favorable reimbursement policies are some of the main factors predicted to boost the growth of the glaucoma therapy market in North America in the coming years.

Prostaglandin Analogues to be the Most Widely Used In Drug Class

Prostaglandin Analogues hold the highest market share in the year 2026. Prostaglandins have changed the face of the care scenario for glaucoma and are used as first-line glaucoma therapy. The segment of prostaglandin analogs represented a significant market share in 2019 and is expected to remain dominant throughout the 2020-2026 forecast period. Besides, the increasing adoption of prostaglandin analogs is likely to favor the growth of the global therapeutic market for glaucoma. Key factors such as government initiatives and population health awareness programs will drive market growth, and postoperative complications that occur after glaucoma surgery will catalyze the global glaucoma therapy market.

North America expected to witness significant growth in the market in the upcoming years

Due to the large health-care system, North America is expected to dominate the glaucoma therapy market. Followed by North America, Europe & Asia-Pacific will lead in the coming years to significant growth in the global glaucoma market. Consistent Increase in Glaucoma Prevalence Rising market growth with the highest rate in the Asia Pacific. The North American region's superiority is due to the US's effective care system for severe ophthalmological disorders, and the provision of well-equipped medical facilities for glaucoma diagnosis. Asia Pacific is expected to see relatively significant CAGR in 2019-2026 due to the increasing number of cases diagnosed with glaucoma in countries such as China and India and efforts being made by public authorities in those countries to prevent and monitor glaucoma. The increasing geriatric population in Japan also contributes to the Asia-Pacific glaucoma therapy market.

Browse Detailed Table of Contents, “Glaucoma Therapeutics Market, By Drug Class (Beta Blockers, Prostaglandins, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Combination Drugs), By Disease Indication (Open Angle Glaucoma, Angle Closure Glaucoma), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Trend Analysis, Competitive Market Share & Forecast, 2016-26


Glaucoma Therapeutics: Competitive Landscape

The major market players in Glaucoma Therapeutics are Merck & Co., Inc., Novartis AG, Allergan plc, Bausch & Lomb Incorporated, Teva Pharmaceutical Industries, Aerie Pharmaceutical, Pfizer Inc., Inotek Pharmaceuticals, Akorn Inc., Santen, and Other Prominent Players.

Novartis AG (Alton) and Allergan dominate the global market for glaucoma therapy. The overall vendor landscape of the glaucoma therapy industry is highly fragmented with various global players. Novartis AG and Allergan accounted for the highest volume market share in 2019. The two companies are engaged in the manufacture and marketing, respectively, of their prostaglandin analogs Travatan and Lumigan, which are favored as the first-line glaucoma treatment option. This has strengthened both companies ' strategic position in the revenues from the glaucoma therapeutics industry.